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Abstract 
Aim: The aim of this audit was to assess 
adherence to local guideline in the management of 
Diabetic Ketoacidosis (DKA). 
Method: Patients admitted with DKA between 
April 2013 and March 2015 were identified and 
data was retrospectively collected from patients’ 
confidential files and Isoft®. Data collected 
included initial parameters recorded and 
biochemical investigations taken (initial and 
subsequent assessment of pH, HCO3-, blood glucose, 
potassium levels and urinary ketones), insulin 
regime started and intravenous fluid administered.  
Results: During the established time period 40 
cases of DKA were identified in 18 patients.  
Median age was 33 years with a female 
preponderance of 60%. Six patients had newly 
diagnosed diabetes mellitus while 8 patients had 
more than one admission of DKA. All cases had 
capillary blood glucose monitoring (BGM) and/or 
venous random blood (plasma) glucose (RBG) 
checked and pH and HCO3- recorded on admission.  
0.9% sodium chloride was the intravenous fluid 
started in all cases (as recommended by the 
guideline) and a median of 6.75L was prescribed 
during the first 24 hours. The median time spent on 
intravenous insulin infusion was 42.7 hours while 
the median time to pH >7.30, HCO3- >15mmol/L 
and negligible urinary ketones were 6.88, 12.83 and 
34.5 hours respectively. Subcutaneous insulin was 
started at a median time of 48.21 hours from 
initiation of DKA protocol.  
Conclusion: This audit showed good adherence 
to local guideline. The great discrepancy between 
the time to pH >7.3 and the time to negligible 
urinary ketones highlights the need to introduce 
tools to measure systemic ketone production in the 
management of DKA with an update in the current 
local clinical practice guideline.  
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Introduction 
Diabetic ketoacidosis (DKA) is defined by the 
biochemical triad of ketone production, 
hyperglycaemia and acidaemia. Although not 
common, mortality from DKA is approximately 
2%,1 however, each death is potentially avoidable. 
Increasing patient and healthcare professional 
education and awareness of DKA and its 
management, has led to a decline in mortality over 
recent years. 
The current audit aimed to assess the 
management of patients with DKA and compare 
these practices with the local DKA guideline issued 
in 2007.3 Changes in current practice that could 
improve patient care and shorten hospital stay will 
be identified and instituted. 
 
Methods 
All adult patients (>16years of age) admitted 
with DKA to Mater Dei Hospital (MDH) over a two 
year period, between April 2013 and March 2015 
were identified. These were identified from the 
Accident and Emergency (A&E) admission book 
and the Electronic Case Summary system. Patients’ 
confidential files and Isoft® investigations were 
analysed in detail and predefined data sets obtained, 
in line with Data Protection Act. Only patients with 
parameters fulfilling the biochemical triad of DKA: 
1) blood glucose > 11.0mmol/L or known to have 
diabetes mellitus, 2) metabolic acidosis with HCO3
- 
<15.0mmol/L and/or venous pH < 7.3 and 3) 
significant ketonuria > 2+ on standard urine sticks, 
were included in the study.4 The identified patients 
had their DKA management analysed in detail and 
compared to the current DKA guideline3 available 
at MDH. All data was recorded on Microsoft Excel 
spreadsheet and analysis of data was then 
performed using IBM SPSS® version 22. 
Kolmogorov–Smirnov test was carried out to 
determine the normal distribution of the data and 
then either T-Test / ANOVA (for parametric data) 
or Mann-Whitney U / Kruskal–Wallis or χ2 (for 
non-parametric data) tests were used as appropriate. 
Correlation analyses were carried out using 
Spearman correlation. 
 
Results 
1. Demographics 
Using the criteria above to define DKA, 40 
cases (n = 40) were identified in a total of 18 
different patients, during the study period. In the 
cases studied the median age was 33 years (IQR 24 
– 52.25) with a female predominance of 60%. Six 
patients (33.3%) had newly diagnosed diabetes. 8 
patients (44.4%) had more than one admission with 
DKA during the studied period.  
 
2. Initial Assessment and investigations 
Vital parameters (temperature (T), systolic 
blood pressure (SBP), Glasgow coma scale (GCS), 
oxygen saturation (SO2%) and pulse (P)) at 
presentation, as documented in casualty were 
analysed (Table 1).  
On admission all patients had recorded bedside 
capillary blood glucose monitoring (BGM). BGM 
was recorded as ‘HI’ in 7 cases, while the median 
reading in 32 cases was 25.7mmol/L (IQR 23.48 – 
30). Venous random blood (plasma) glucose (RBG) 
was documented in 29 cases and the median was 
33.6mmol/L (IQR 25.2 – 37.4). All 40 cases had pH 
and HCO3
- levels checked, in 33 cases by an arterial 
blood gas (ABG) and 7 cases by a venous blood gas 
(VBG) analysis. The median pH of the study 
population at presentation was 7.18 (IQR 7.11 – 
7.24) while the median value for HCO3
- was 7.4 
(IQR 5.4 – 11.45). A urine sample confirming 
ketonuria was obtained in 22 cases in the A&E 
Department.  
Additional investigations recommended by the 
current DKA guideline3 include a complete blood 
count (CBC), renal profile (U&E, Cr), arterial blood 
gases (ABG), urinalysis, pregnancy test in female 
patients, ECG and chest x-ray (CXR). An amylase 
level is recommended in patients with abdominal 
pain. The frequency and results of these tests in 
concordance to the local guideline is illustrated in 
Table 1. 
All cases were admitted to Mater Dei Hospital, 
with 4 cases requiring admission to intensive 
therapy unit (ITU).  
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Table 1: Parameters and investigations with respective median results measured at admission 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Frequency of ABG/VBG testing with median results for pH and HCO3
- 
Time of 
ABG/VBG 
(hrs from start 
of protocol) 
Frequency 
(n) 
Percentage 
(%) 
Median pH 
(mmHg) (IQR) 
Median HCO3-  
(mmol/L) (IQR) 
0 40 100 7.19 (7.11 - 7.25) 7.4 (5.4 - 11.45) 
2 33 82.5 7.22 (7.18 - 7.27) 8.7 (5.4 - 13.2) 
4 29 72.5 7.27 (7.22 - 7.31) 8.6 (7.2 - 13.7) 
8 35 87.5 7.33 (7.28 - 7.37) 14 (12.2 - 16.6) 
12 33 82.5 7.36 (7.34 - 7.40) 16.6 (15.4 - 19.0) 
24 14 35 7.42 (7.36 - 7.43) 18 (16.6 - 20.5) 
 
 
 
 
 
 
 
Parameters and 
investigations on 
admission 
Frequency (n) Median (Interquartile Range) 
Temperature (℃) 38 36.4 (36 - 36.8) 
GCS 40 15 
Oxygen saturation (%) 37 99 (98 - 99) 
SBP (mmHg) 39 121 (107 - 134.5) 
Pulse rate (/min) 39 103 (93 - 120) 
White cell count (x109/L) 40 13.55 (8.78 - 19.98) 
Creatinine (μmol/L) 40 104 ( 94.75 - 120.5) 
eGFR (mls/min/1.73m2) 40 60.5 (48.25 - 71.25) 
Amylase (U/l) 24 39 (35 - 76.75) 
ECG 39 n/a 
CXR 33 n/a 
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Table 3: Frequency of K level checked and median level at time interval 0, 2, 4, 8, 12 and 24 hours from start 
of DKA protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. ABGs/VBGs 
According to current local DKA guideline, pH 
and HCO3
- should be measured at 2, 4, 8, 12 hours 
after starting the protocol or until normalisation of 
metabolic acidosis. All patients had ABGs/VBGs 
repeated until pH and HCO3
- levels had normalised 
but not necessarily within the stipulated time 
intervals (see table 2). 
 
4. Ketones 
The current DKA guideline recommends 
measuring urinary ketones every 4 hours until 
clearance is achieved. Ketones were checked 
regularly in 38 cases (95%) during the first 24 
hours, while 29 patients still required urinary ketone 
testing for more than 24 hours after starting DKA 
treatment protocol. In the initial 24 hours after 
starting treatment the median number of times 
urinalysis was performed was 4 times (IQR 3 – 
5.75) with a median of 2 times (IQR 1 – 3) at 24 – 
48 hours.  
 
5. BGM  
Hourly BGM checks are recommended in the 
current local DKA guideline, for patients on 
intravenous insulin infusion. The median number of 
BGM checked was 17.5 times (IQR 9.75 – 22.25) 
during the first 24 hours and 4 times (IQR 3 – 5.75) 
at 24 – 48 hours from admission. 
 
6. Insulin administration 
All cases studied were treated with a variable-
rate insulin infusion (VRIII) of short-acting insulin 
(Actrapid®). Long-acting basal insulin together with 
intravenous Actrapid® was co-administered in 4 
cases (10%). The median time spent on Actrapid® 
infusion was 42.7 hours (IQR 27.9 – 65.75). During 
this period of time the median number of units of 
insulin required was 89Units (IQR 65 – 114) in the 
first 24 hours of protocol and 66Units (IQR 54.5 – 
83) at 24 – 48 hours. Total insulin dose in the first 
24 hours was positively correlated with initial RBG 
(ρ=0.381, P= 0.024). In 7 cases (18%), a further 
increase in insulin was required to reach target 
BGM. 
 
7. Intravenous fluids 
All patients were started on 0.9% of sodium 
chloride in concordance with the local guideline. 
The patients received a median of 6.75L (IQR 6.11 
– 7.45L) during the first 24 hours. 10 cases (25%) 
did not require intravenous fluid for more than 24 
hours, while 30 cases (75%) received a median of 
2L (IQR 0.5 – 2.72L) at 24 – 48 hours from starting 
DKA protocol. 
Intravenous fluids are to be changed to 5% 
dextrose in normal saline if BGM is less than 
11mmol/L and to 10% dextrose if BGM is less than 
5mmol/L in the current local DKA guideline. 
Intravenous fluids were correctly changed in 36 
cases when BGM fell below 11mmol/L. In 10 cases 
BGM fell less than 5mmol/L during the initial 24 
hours and 9 of these cases had the intravenous fluid 
correctly changed to 10% dextrose.  
 
 
 
 
 
 
 
 
Time of K  
(hrs from start of protocol) 
Frequency of K level checked n 
(%) 
Median K level (mmol/L) 
(IQR) 
0 40 (100) 4.7 (4.2 – 5.1) 
2 31 (78) 4 (3.4 - 4.4) 
4 29 (73) 4.3 (3.9 - 4.5) 
8 35 (88) 3.8 (3.5 - 4.4) 
12 32 (80) 3.9 (3.5 - 4.1) 
24 22 (55) 3.7 (3.2 - 4.1) 
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Table 4:  Correlation between different parameters in DKA management 
 Results in bold are statically significant (P<0.05) p: Spearman rank-order correlation coefficient; P: Significance (two-tailed)   
 Initial pH 
Initial 
RBG 
Age 
Systolic 
BP on 
admission 
Initial 
Potassium 
WCC on 
admission 
eGFR on 
admission 
Total 
Insulin 
given in 
1st 24 hrs 
Time 
Period till 
pH.>7.3 
Time 
Period till  
HCO3-  
>15 
Time 
Period till 
urine 
Ketones -
ve 
Hours on 
Actrapid 
pump 
HCO3- 
ρ 0.560 -0.323 -0.500 -0.386 0.070 -0.630 0.487 -0.296 -0.396 -0.0630 -0.444 -0.497 
P <0.001 0.058 0.764 0.017 0.672 <0.001 0.002 0.071 0.014 <0.001 0.023 0.001 
Initial pH  
ρ  -0.041 0.304 -0.231 0.002 -0.253 0.200 0.072 -0.579 -0.520 -0.141 0.026 
P  0.814 .056 0.158 0.991 0.115 0.216 0.662 <0.001 0.001 0.483 0.872 
Initial RBG 
ρ   0.475 -0.309 0.406 0.419 -0.747 0.381 0.108 0.140 0.409 0.544 
P   0.003 0.066 0.014 0.009 <0.001 0.024 0.530 0.429 0.038 0.001 
Age 
ρ    0.074 0.314 0.194 -0.325 0.244 -0.046 -0.150 -0.090 0.333 
P    0.655 0.049 0.231 0.041 0.134 0.781 0.370 0.654 0.036 
Systolic BP on 
admission 
ρ     -0.236 0.028 0.181 -0.080 0.237 0.200 -0.302 0.020 
P     0.148 0.865 0.271 0.633 0.152 0.235 0.125 0.905 
Initial Potassium 
ρ      0.288 -0.191 -0.036 -0.127 0.017 -0.039 0.104 
P      0.072 0.238 0.825 0.441 0.919 0.849 0.523 
WCC on 
admission 
ρ       -0.406 0.349 0.224 0.500 0.545 0.566 
P       0.009 0.029 0.170 0.001 0.003 <0.001 
eGFR on 
admission 
ρ        -0.328 -0.264 -0.309 -0.325 -0.589 
P        0.041 0.105 0.059 0.098 <0.001 
Total Insulin 
given in 1st 24 hrs 
ρ         -0.050 0.182 0.091 0.403 
P         0.767 0.281 0.658 0.011 
Time Period till 
pH.>7.3   
ρ          0.544 0.015 0.165 
P          0.001 0.941 0.315 
Time Period till  
HCO3-  >15 
ρ         0.544  0.494 0.390 
P         0.001  0.010 0.015 
Time Period till 
urine Ketones -ve 
ρ         0.015 0.494  0.436 
P         0.941 0.010  0.023 
Hours on 
Actrapid pump 
ρ         0.165 0.390 0.436  
P         0.315 0.015 0.023  
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8. Potassium supplementation 
The current guideline suggests checking 
potassium (K) levels at 2, 4, 8, and 12 hours and to 
add supplemental potassium chloride into the 
intravenous fluid solution according to results.  
Table 3 shows frequency and results of K level at 
the time intervals recommended. Correlation 
analysis showed K levels at presentation to be 
positively correlated with increasing age and RBG 
(ρ=0.314, P=0.049 and ρ=0.406, P=0.014 
respectively). (Table 4) 
 
9. Additional management 
In 7 cases insulin was infused via pump at a 
higher rate than recommended by protocol while in 
2 cases the intravenous fluids prescribed after 
admission differed by both rate (infused at a 
standard rate of 128mL/min) and type (Hartmann’s 
solution) respectively from what is recommended in 
the guideline. Furthermore, 2 patients were 
prescribed sodium bicarbonate. 
Antibiotics were prescribed in 23 patients. 10 
patients had no documented source of infection, 5 
patients had documented respiratory tract infection, 
4 patients had a urinary tract infection, 2 patients 
had gastroenteritis while one patient had antibiotics 
started for pelvic inflammatory disease. White cell 
count on admission was found to be negatively 
correlated with initial HCO3
- and eGFR (ρ=-0.630, 
P=<0.01 and ρ=-0.406, P=0.009 respectively), but 
positively correlated with initial RBG levels 
(ρ=0.419, P=0.009) and time to resolution of DKA 
(ρ=0.545, P=<0.01) (Table 4).  
Urinary catheterisation was performed in 11 
cases during admission. Reason for catheterisation 
was documented as haemodynamic instability in 5 
cases, acute kidney injury in 4 cases and in 2 cases 
this was undocumented.  
 
10. Time to resolution of DKA 
According to our local guidelines, DKA is 
considered resolved and fixed doses of 
subcutaneous insulin are recommended to be 
restarted once pH and bicarbonate are normal, 
normoglycaemia is achieved, urine is free of 
ketones and patient is eating normally. Using these 
criteria time to resolution of DKA and time spent 
on DKA protocol (taken as the time to 
subcutaneous insulin) were determined. These 
results are shown in Figure 1.  Most of the 4 
variables which were taken as indicative of 
resolution of DKA correlated positively with each 
other as shown in Table 4. 
 
Discussion 
The main aim of this audit was to assess 
adherence of current practices to the local 
guidelines and identify areas for improvement in the 
management of DKA. 
From the whole cohort, 8 patients had more 
than one admission. Seven patients had 2 
admissions and one patient had 11 admissions. 
Recurrent admissions with DKA is associated with 
multiple factors including poor control, 
noncompliance and nonattendance to outpatient 
clinic, female gender, presence of co-morbidity and 
psychological problems.2 From the cohort of 
patients with readmissions, 6 patients were females, 
4 patients were non-compliant to treatment, 1 
patient had underlying pancreatic tumour and 1 
patient had steroid-induced DKA. The patient with 
11 admissions with DKA had an underlying 
psychological disorder. 
All patients had BGM checked on admission. 
Median RBG was noted to be significantly higher 
than median BGM (33.6mmol/L and 25.7mmol/L 
respectively). In 7 cases (17.5%) the BGM value 
was unrecordable as point of care machines are not 
able to give a numerical reading at very high levels. 
The median BGM was therefore underestimated as 
these 7 cases were excluded from the calculated 
BGM median.  
Deviation from protocol was noted in some 
cases. All 40 cases had pH and bicarbonate levels 
measured. 33 cases (82.5%) had an ABG 
measurement, whilst 7 cases (17.5%) had a VBG 
measurement on admission. Current local guideline 
recommends taking ABGs until normalisation of 
pH and taking VBGs in difficult cases if general 
condition is improving.3 Guidelines issued by the 
Joint British Diabetes Societies (JBDS) Inpatient 
Care Group4 suggest measuring venous rather than 
arterial bicarbonate and pH as the difference 
between venous and arterial pH is 0.02 – 0.15 pH 
units and the difference between arterial and venous 
bicarbonate is 1.88mmol/L. This negligible 
difference will neither impact diagnosis nor 
management of DKA.5 
In 18 cases (45%) a urine sample was not 
available for measuring urinary ketones at the A&E 
department for various reasons including inability 
of patients to pass urine, dehydration and low GCS. 
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According to the JBDS guidelines one of the 
criteria defining DKA is a serum ketonaemia of ≥ 
3.0mmol/L or significant ketonuria of ≥ 2+ on 
standard urine sticks.4 Locally ketone meters are not 
available yet and this may delay the detection of 
ketones in patients who are unable to provide a 
urine sample at A&E. Ketone meters detect β-
hydroxybutyrate which is the main type of ketone 
produced in DKA as opposed to acetoacetate 
detected by the standard urine dipsticks. The latter 
also sometimes gives false positive results and the 
presence of acetoacetate in urine lags behind the 
actual systemic ketone production, therefore 
delaying both diagnosis and resolution of DKA.6 
Local guideline recommends use of a VRII and 
in 7 cases (18%), a further increase in insulin 
treatment recommended. Updates in JBDS 
guideline suggest using a fixed-rate insulin infusion 
(FRII) rather than VRII. FRII consists of 
prescribing a fixed insulin regime according to 
weight, thus partially accommodating for the very 
obese patients4 and enabling rapid ketone clearance. 
In 4 cases (10%) long-acting insulin (glargine) was 
continued together with intravenous short-acting 
insulin infusion. Continued use of background 
insulin avoids rebound hyperglycaemia when 
intravenous insulin is stopped and should also 
shorten duration of inpatient stay.7          
Initial intravenous fluid recommended in 
current guideline is 0.9% NaCl, which is to be 
changed to 5% dextrose in 0.9% NaCl if BGM < 
11mmol/L and to 10% dextrose if BGM 
<5mmol/L3. This recommendation was adhered to 
in 36 cases (90%). This represents a significant 
improvement from observations in a previous audit, 
in which correct change in intravenous fluids was 
observed in 71.4% of cases.8  Patients in DKA often 
have mild to moderate hyperkalaemia at diagnosis, 
despite a total body deficit of potassium. The 
initiation of insulin further lowers circulating 
potassium as it shifts potassium intracellularly, 
potentially resulting in severe hypokalaemia.9  
Hence close attention needs to be given to 
potassium levels, in order to avoid complications 
associated with hypokalaemia, including cardiac 
arrhythmias, arrest and respiratory muscle 
weakness.4 Data on potassium supplementation 
differs. The American Diabetes association 
guidelines suggest the addition of 20-30mmol of 
potassium in each litre of infusion fluid to maintain 
a potassium level between 4 and 5mmol/l,10 
whereas the JBDS guidelines4 recommend replacing 
with a dose of 40mmol/L of potassium if serum 
level is less than 5.5mmol/l. 
An elevated WCC was negatively correlated 
with HCO3- and pH levels, although the latter did 
not reach statistical significance (p = <0.001 and p 
= 0.115 respectively). DKA is associated with an 
elevated level of proinflammatory cytokines, 
reactive oxygen species, and adhesion molecules 
which all contribute to the increased WCC.11 
Assessment of resolution of DKA was based on 
normalisation of pH, HCO3- and urinary ketones 
level. From our results, pH levels returned to 
normal at the shortest time interval, followed by 
HCO3- and urinary ketones respectively (Fig. 1). 
From our data HCO3
- correlated well with the 2 
other variables measured for the resolution of DKA. 
However JBDS guidelines recommend not using 
HCO3- as the only variable due to possible 
hyperchloraemia secondary to large volumes of 
0.9% sodium chloride solution used as fluid 
replacement. Consequent hyperchloraemic acidosis 
may lower HCO3- levels and lead to difficulty in 
assessing for resolution of ketosis.4   
The limitations of this audit include missing 
data from files and observation charts. Unclear and 
incomplete documentation also limited extraction of 
relevant data for this audit. Nonetheless, the audit 
performed showed numerous strengths including 
correct diagnosis of patients on presentation to 
A&E, accurate assessment of fluid balance and 
BGM management, accurate documentation of time 
at which subcutaneous insulin was restarted and of 
resolution of DKA.  
 
Conclusion 
In the current local guideline the diagnosis and 
resolution of DKA is based on pH, bicarbonate and 
detection /lack of ketones in the urine. Results from 
our audit for resolution of DKA have highlighted 
the great discrepancy between the time taken to 
achieve a pH >7.3mmHg (7.38hrs) and the time 
taken to achieve negative ketones in the urine 
(26.25hrs). The difficulty in obtaining a urine 
sample to test for ketones early on presentation and 
the persistent detection of ketones in the urine after 
suppression of ketonaemia contribute to the delay in 
diagnosing DKA and in identifying resolution of 
DKA respectively. This might result in potentially 
harmful delays in initiating treatment of DKA and 
subsequent unnecessary prolonged treatment with 
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insulin infusion. The introduction of ketone meters 
to measure ketones in the blood would expedite 
DKA diagnosis, facilitate monitoring of the patient 
admitted with DKA and accurately identify 
resolution of DKA early while the administration of 
insulin infusion at a fixed rate, tailored to the 
individual patient according to the patient’s weight, 
would contribute to rapid ketone clearance thus 
improving the overall management of the patient 
admitted with DKA. 
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